[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350743-105":59,"doc-detail-350743-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","raccdc42-inhibitors-target-pancreatic-cancer-cells-and-macrophages-in-the-tumor-microenvironment","Rac/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment","","Pancreatic ductal adenocarcinoma (PDAC) persists as a highly lethal cancer shaped by an immunosuppressive tumor microenvironment and a distinct extracellular matrix. A key unmet need is therapies that act on both metastatic cancer cells and tumor-associated macrophages (TAMs). The Ras-regulated GTPases Rac and Cdc42, which signal via p21-activated kinase (PAK), are poor prognostic factors and potential targets. Phospho-PAK was elevated in invasive PDAC tissues from Puerto Rican patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/raccdc42-inhibitors-target-pancreatic-cancer-cells-and-macrophages-in-the-tumor-microenvironment/350743/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/raccdc42-inhibitors-target-pancreatic-cancer-cells-and-macrophages-in-the-tumor-microenvironment/350743.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are Rac and Cdc42 considered targets for PDAC therapy?","Question",{"text":112,"@type":113},"Rac and Cdc42 regulate migration/invasion, cell polarity/morphology, and cell viability/survival in cancer and immune cells, largely through p21-activated kinase (PAK) signaling. Their pathway components are linked to poor prognosis in PDAC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What dual inhibitors were evaluated in the study?",{"text":117,"@type":113},"The study tested MBQ-167 and MBQ-168 as dual Rac/Cdc42 inhibitors in both PDAC cells and macrophages, using biochemical activation assays and functional cellular assays.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main reported effects of MBQ-167 and MBQ-168?",{"text":121,"@type":113},"The inhibitors significantly reduced active Rac and Cdc42 in pancreatic and macrophage cells, decreased cancer cell migration in co-culture, inhibited morphology and migration of both cell types, and reduced inflammatory mediators including IL-6, CHI3L1, and S100A8/A9.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350743,1790164282,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cancer Treat Res Commun. Author manuscript; available in PMC 2026 August 27. |\n| --- | --- |\n\nPublished in final edited form as:  \nCancer Treat Res Commun. 2026 ; 48: 101335. doi:10.1016/j.ctarc.2026.101335 .  \nRac/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment  \nAnamaris Torres-Sancheza, Stephanie Dorta-Estremerab,c, Victor P. Carlod, Suranganie Dharmawardhanea,c,e,*  \na Department of Biochemistry, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA  \nb Department of Microbiology and Medical Zoology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA  \ncCancer Biology Division, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, USA  \nd Department of Pathology, Auxilio Mutuo Hospital, San Juan, PR, USA eMBQ-Pharma, Inc. , San Juan, PR, USA  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest forms of cancer, with a distinct extracellular matrix and immunosuppressive tumor microenvironment. Therefore, there is a critical need for therapies that simultaneously target metastatic cancer cells and immunosuppressive cells such as tumor associated macrophages (TAMS) that promote pancreatic cancer progression. Ras-activated homologous GTPases Rac and Cdc42 are ideal targets for pancreatic cancer therapy because they regulate cell migration/invasion, cell polarity/morphology, and cell viability/survival in cancer cells and immune cells, mainly through activation of their common downstream effector p21-activated kinase (PAK) via autophosphorylation. Rac, Cdc42, and PAK are poor prognostic factors in PDAC. Accordingly, we found phospho-PAK levels to be elevated in invasive PDAC from Puerto Rican patient tissue. The potential of the dual Rac/Cdc42 inhibitors MBQ-167 and MBQ-168 were tested in human and mouse PDAC cells or macrophages by pulldown assays for Rac and Cdc42 activation, MTT assays for cell viability, wound-healing assays for cell migration, phagocytosis, as well as co-culture assays with PDAC cells and macrophages. Results show that Rac/Cdc42 inhibitors significantly reduce active Rac and Cdc42 in pancreatic and macrophage cells. Both MBQ-167 and MBQ-168 reduced pancreatic  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*Corresponding author at: Department of Biochemistry, University of Puerto Rico Medical Sciences Campus, PO Box 365067, San Juan, PR, [00936. su.d@upr.edu](00936. su.d@upr.edu) (S. Dharmawardhane).  \nCRediT authorship contribution statement  \nAnamaris Torres-Sanchez: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Data curation. Stephanie Dorta-Estremera: Validation, Supervision, Formal analysis. Victor P. Carlo: Visualization, Validation, Supervision. Suranganie Dharmawardhane: Writing – review & editing, Validation, Supervision, Resources, Project administration, Conceptualization.  \nDeclaration of competing interest  \nSuranganie Dharmawardhane reports patents for MBQ-167 and MBQ-168 (US 9981,980 B2, 10,392,396), which are licensed to MBQ Pharma, Inc. SD holds stock in MBQ Pharma, Inc.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nTorres-Sanchez et al. Page 2  \ncancer cell viability with higher efficacy than macrophage viability, and inhibited morphology and migration of both cell types. In Transwell co-culture, MBQ-167 and MBQ 168 decreased pancreatic cancer cell migration and reduced inflammatory mediators such as Interleukin-6 (IL-6), Chinase-3-like protein 1 (CHI3L1) and S100A8/A9 (calprotectin) . Therefore, MBQ-167 and MBQ-168 are potential PDAC therapeutics by targeting both pancreatic cancer","cbCail9y7xIFMu1H","https://ap.wps.com/l/cbCail9y7xIFMu1H","pdf",2265970,28,"English","# Abstract\n# Introduction\n# Keywords\n# Methods and Results\n## Dual Rac/Cdc42 inhibitor testing\n## Effects on migration, viability, and inflammatory mediators\n# Conclusion","[{\"question\":\"Why are Rac and Cdc42 considered targets for PDAC therapy?\",\"answer\":\"Rac and Cdc42 regulate migration/invasion, cell polarity/morphology, and cell viability/survival in cancer and immune cells, largely through p21-activated kinase (PAK) signaling. Their pathway components are linked to poor prognosis in PDAC.\"},{\"question\":\"What dual inhibitors were evaluated in the study?\",\"answer\":\"The study tested MBQ-167 and MBQ-168 as dual Rac/Cdc42 inhibitors in both PDAC cells and macrophages, using biochemical activation assays and functional cellular assays.\"},{\"question\":\"What were the main reported effects of MBQ-167 and MBQ-168?\",\"answer\":\"The inhibitors significantly reduced active Rac and Cdc42 in pancreatic and macrophage cells, decreased cancer cell migration in co-culture, inhibited morphology and migration of both cell types, and reduced inflammatory mediators including IL-6, CHI3L1, and S100A8/A9.\"}]","Rac/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment | PDF",1790090847,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aafb8046dae8fc2596766783d89c875d.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e684c1ee19a42ec530190f6a25fd96a.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c78e2392fd188423de456da693eb662.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fefc33b896f33ec7cfe408773deea431.webp",980,1268]